AU2012315421C1 - Increasing virus-like particle yield in plants - Google Patents

Increasing virus-like particle yield in plants Download PDF

Info

Publication number
AU2012315421C1
AU2012315421C1 AU2012315421A AU2012315421A AU2012315421C1 AU 2012315421 C1 AU2012315421 C1 AU 2012315421C1 AU 2012315421 A AU2012315421 A AU 2012315421A AU 2012315421 A AU2012315421 A AU 2012315421A AU 2012315421 C1 AU2012315421 C1 AU 2012315421C1
Authority
AU
Australia
Prior art keywords
plant
protein
seq
influenza
vlp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012315421A
Other languages
English (en)
Other versions
AU2012315421B2 (en
AU2012315421A1 (en
Inventor
Manon Couture
Marc-Andre D'aoust
Louis-Philippe Vezina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aramis Biotechnologies Inc
Original Assignee
Aramis Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aramis Biotechnologies Inc filed Critical Aramis Biotechnologies Inc
Publication of AU2012315421A1 publication Critical patent/AU2012315421A1/en
Publication of AU2012315421B2 publication Critical patent/AU2012315421B2/en
Application granted granted Critical
Publication of AU2012315421C1 publication Critical patent/AU2012315421C1/en
Assigned to ARAMIS BIOTECHNOLOGIES INC. reassignment ARAMIS BIOTECHNOLOGIES INC. Request for Assignment Assignors: MEDICAGO INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16223—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2012315421A 2011-09-30 2012-09-28 Increasing virus-like particle yield in plants Active AU2012315421C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161541780P 2011-09-30 2011-09-30
US61/541,780 2011-09-30
PCT/CA2012/050681 WO2013044390A1 (en) 2011-09-30 2012-09-28 Increasing virus-like particle yield in plants

Publications (3)

Publication Number Publication Date
AU2012315421A1 AU2012315421A1 (en) 2014-04-10
AU2012315421B2 AU2012315421B2 (en) 2017-10-19
AU2012315421C1 true AU2012315421C1 (en) 2019-12-05

Family

ID=47994080

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012315421A Active AU2012315421C1 (en) 2011-09-30 2012-09-28 Increasing virus-like particle yield in plants

Country Status (27)

Country Link
US (1) US11155581B2 (enExample)
EP (2) EP3626733B1 (enExample)
JP (1) JP6248040B2 (enExample)
KR (1) KR101974017B1 (enExample)
CN (2) CN103930435A (enExample)
AU (1) AU2012315421C1 (enExample)
BR (1) BR112014007474A2 (enExample)
CA (1) CA2850407C (enExample)
DK (1) DK2760882T5 (enExample)
ES (1) ES2951259T3 (enExample)
FI (1) FI2760882T3 (enExample)
HR (1) HRP20230695T1 (enExample)
HU (1) HUE062759T2 (enExample)
IL (1) IL231587B (enExample)
IN (1) IN2014CN03077A (enExample)
MX (2) MX358883B (enExample)
MY (1) MY184072A (enExample)
NZ (1) NZ622731A (enExample)
PH (1) PH12014500640A1 (enExample)
PL (1) PL2760882T3 (enExample)
PT (1) PT2760882T (enExample)
RU (1) RU2682752C2 (enExample)
SG (2) SG10201708052XA (enExample)
SI (1) SI2760882T1 (enExample)
TW (1) TWI700368B (enExample)
WO (1) WO2013044390A1 (enExample)
ZA (1) ZA201403059B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11390878B2 (en) 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
CA2850407C (en) 2011-09-30 2021-11-23 Medicago Inc. Increasing virus-like particle yield in plants
US12467058B2 (en) 2013-03-28 2025-11-11 Aramis Biotechnologies Inc. Influenza virus-like particle production in plants
JP2016516415A (ja) 2013-03-28 2016-06-09 メディカゴ インコーポレイテッド 植物におけるインフルエンザウイルス様粒子の生成
DK3092309T3 (da) * 2014-01-10 2021-04-12 Medicago Inc Cpmv-forstærkerelementer
WO2015143567A1 (en) 2014-03-27 2015-10-01 Medicago Inc. Modified cpmv enhancer elements
MX2020009495A (es) * 2018-03-14 2020-12-07 Medicago Inc Potenciador de la expresion en plantas.
MX2020013961A (es) * 2018-06-27 2021-03-09 Medicago Inc Mutantes de hemaglutinina del virus de la influenza.
JP7512546B2 (ja) * 2019-03-14 2024-07-09 アラミス バイオテクノロジーズ インコーポレイテッド 内因性植物発現エンハンサー
WO2021236908A2 (en) * 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011102900A1 (en) * 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428147A (en) 1983-04-15 1995-06-27 Mycogen Plant Science, Inc. Octopine T-DNA promoters
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4962028A (en) 1986-07-09 1990-10-09 Dna Plant Technology Corporation Plant promotors
US5232833A (en) 1988-09-14 1993-08-03 Stressgen Biotechnologies Corporation Accumulation of heat shock proteins for evaluating biological damage due to chronic exposure of an organism to sublethal levels of pollutants
US5805417A (en) 1995-10-13 1998-09-08 Hitachi, Ltd. Heat dissipation structure in a portable computer including a heat dissipation block extending from a heat dissipation plate through a first circuit board to a CPU on a second circuit board
AU6512299A (en) 1998-10-07 2000-04-26 Boyce Institute For Plant Research At Cornell University Gemini virus vectors for gene expression in plants
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
RU2164148C1 (ru) * 2000-08-09 2001-03-20 Петров Рэм Викторович Вакцина против вируса гриппа и способ ее получения
NZ543348A (en) * 2003-05-05 2008-08-29 Thompson Boyce Plant Res Vectors and cells for preparing immunoprotective compositions derived from transgenic plants
CA2524799A1 (en) 2003-05-05 2004-11-18 Dow Agrosciences Llc Stable immunoprophylactic and therapeutic compositions derived from transgenic plant cells and methods for production
PL1883701T3 (pl) * 2005-04-29 2012-06-29 Univ Cape Town Ekspresja białek wirusa w roślinach
US7871626B2 (en) * 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
SI1937301T1 (sl) * 2005-10-18 2015-08-31 Novavax, Inc. Funkcionalni influenčnemu virusu podobni delci (VLP)
CA2627105A1 (en) * 2005-10-26 2007-05-03 Protelix, Inc. Influenza combinatorial antigen vaccine
SG169996A1 (en) * 2006-02-16 2011-04-29 Us Gov Health & Human Serv Antiviral agents and vaccines against influenza
AU2007224034B2 (en) 2006-03-07 2012-03-29 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
EP1998814A4 (en) 2006-05-11 2010-06-16 Novavax Inc NEW VACCINES AGAINST INFLUENZA M2
EP2029755A1 (en) 2006-05-22 2009-03-04 Plant Bioscience Limited Bipartite system, method and composition for the constitutive and inducible expression of high levels of foreign proteins in plants
CA2654178A1 (en) * 2006-06-16 2007-12-27 Dow Agrosciences Llc Novel dna sequences, vectors and proteins of avian influenza hemagglutinin
US8697088B2 (en) 2007-05-25 2014-04-15 Novavax, Inc. VLPs derived from cells that do not express a viral matrix or core protein
NZ581944A (en) 2007-06-15 2012-03-30 Medicago Inc Modifying glycoprotein production in plants
AU2009202819B2 (en) * 2007-07-13 2014-08-28 Aramis Biotechnologies Inc. Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin
CA2615372A1 (en) * 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
GB0800272D0 (en) 2008-01-08 2008-02-13 Plant Bioscience Ltd Protein expression systems
EA034733B1 (ru) 2008-01-21 2020-03-13 Медикаго Инк. Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
EP2294202B1 (en) 2008-07-08 2015-05-20 Medicago Inc. Soluble recombinant influenza antigens
PT2318530T (pt) 2008-07-18 2016-09-30 Medicago Inc Novo epítopo de imunização contra o vírus da gripe
CA2736796A1 (en) 2008-08-27 2010-03-04 Arizona Board Of Regents For And On Behalf Of Arizona State University A dna replicon system for high-level rapid production of vaccines and monoclonal antibody therapeutics in plants
JP2012521786A (ja) * 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
CN102482328B (zh) 2009-06-24 2014-11-26 麦迪卡格公司 包含血凝素的嵌合流感病毒样颗粒
FR2947875B1 (fr) 2009-07-10 2011-07-08 Raymond A & Cie Dispositif de fixation a elements de fixation multiples dont l'un est flottant
WO2011011390A1 (en) 2009-07-20 2011-01-27 Novavax, Inc. Purified recombinant influenza virus ha proteins
SI2480560T1 (en) 2009-09-22 2018-04-30 Medicago Inc. A process for preparing proteins derived from plants
CA2813078A1 (en) 2010-10-04 2012-04-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
TWI526539B (zh) 2010-12-22 2016-03-21 苜蓿股份有限公司 植物中生產類病毒顆粒(vlp)的方法及以該方法生產之vlp
PL220281B1 (pl) 2011-09-23 2015-09-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA
CA2850407C (en) 2011-09-30 2021-11-23 Medicago Inc. Increasing virus-like particle yield in plants
US11390878B2 (en) * 2011-09-30 2022-07-19 Medicago Inc. Increasing protein yield in plants
JP6205359B2 (ja) 2012-07-23 2017-09-27 有限会社生物資源研究所 ワクチン
JP2016516415A (ja) 2013-03-28 2016-06-09 メディカゴ インコーポレイテッド 植物におけるインフルエンザウイルス様粒子の生成

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011102900A1 (en) * 2010-02-18 2011-08-25 Technovax, Inc. Universal virus-like particle (vlp) influenza vaccines

Also Published As

Publication number Publication date
TWI700368B (zh) 2020-08-01
EP2760882A4 (en) 2015-06-10
PT2760882T (pt) 2023-08-07
MX358883B (es) 2018-08-31
IL231587B (en) 2020-06-30
TW201329235A (zh) 2013-07-16
PH12014500640A1 (en) 2014-05-05
SG11201400712VA (en) 2014-04-28
KR101974017B1 (ko) 2019-04-30
RU2682752C2 (ru) 2019-03-21
BR112014007474A2 (pt) 2017-04-04
KR20140068260A (ko) 2014-06-05
MX2014003776A (es) 2014-08-21
FI2760882T3 (fi) 2023-07-17
IN2014CN03077A (enExample) 2015-07-03
EP3626733A1 (en) 2020-03-25
CA2850407A1 (en) 2013-04-04
MY184072A (en) 2021-03-17
CN103930435A (zh) 2014-07-16
HRP20230695T1 (hr) 2023-12-22
AU2012315421B2 (en) 2017-10-19
AU2012315421A1 (en) 2014-04-10
CA2850407C (en) 2021-11-23
HUE062759T2 (hu) 2023-12-28
JP2014530006A (ja) 2014-11-17
EP3626733B1 (en) 2024-01-24
JP6248040B2 (ja) 2017-12-13
WO2013044390A1 (en) 2013-04-04
NZ622731A (en) 2016-04-29
ES2951259T3 (es) 2023-10-19
DK2760882T5 (da) 2024-06-24
IL231587A0 (en) 2014-05-28
SG10201708052XA (en) 2017-11-29
US20150104480A1 (en) 2015-04-16
PL2760882T3 (pl) 2023-09-11
ZA201403059B (en) 2019-07-31
SI2760882T1 (sl) 2023-10-30
EP2760882A1 (en) 2014-08-06
EP2760882B1 (en) 2023-05-24
HK1200179A1 (en) 2015-07-31
DK2760882T3 (da) 2023-07-03
CN116218900A (zh) 2023-06-06
US11155581B2 (en) 2021-10-26
MX2018006627A (es) 2020-11-12
RU2014116371A (ru) 2015-11-10

Similar Documents

Publication Publication Date Title
US20230044454A1 (en) Recombinant influenza virus-like particles (vlps) produced in transgenic plants
US10272148B2 (en) Chimeric influenza virus-like particles comprising hemagglutinin
JP5990207B2 (ja) ヘマグルチニンを発現するトランスジェニック植物において産生された組換え型インフルエンザウイルス様粒子（ｖｌｐ）
CA2730185C (en) Influenza virus-like particles (vlps) comprising hemagglutinin
AU2012315421C1 (en) Increasing virus-like particle yield in plants
US11390878B2 (en) Increasing protein yield in plants
HK1200179B (en) Increasing virus-like particle yield in plants
BRPI0906960B1 (pt) Ácido nucleico compreendendo uma sequência de nucleotídeos codificando uma hemaglutinina do vírus de influenza (ha), partículas semelhantes a vírus (vlps), seu método de produção, composição e uso dos mesmos
HK1170250B (en) Chimeric influenza virus-like particles comprising hemagglutinin

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 NOV 2017

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 JAN 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 NOV 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 JAN 2018

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 01 AUG 2019

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 01 AUG 2019

PC Assignment registered

Owner name: ARAMIS BIOTECHNOLOGIES INC.

Free format text: FORMER OWNER(S): MEDICAGO INC.